Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) recorded a 416% rise in attributable profit for the year 2025 to 173.2 million yuan from 33.5 million yuan a year prior, according to a Thursday Hong Kong bourse filing.
Basic EPS stood at 0.43 yuan in the period, up from 0.08 yuan in the last corresponding year.
The pharmaceutical company's total operating revenue jumped 41% to 1.38 billion yuan from 980.5 million yuan previously.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments